Translator Disclaimer
1 March 2014 Evaluation of chelators administered to rescue human bone cells from cadmium toxicity
Megan K. Judkins, Paris S. Humphries, Peter R. Craig
Author Affiliations +

The MTT assay was used to quantify the viability of human osteosarcoma cells (Saos-2) in the presence of chelators administered to alleviate cadmium-mediated cytotoxicity. The chelators evaluated were potassium bis(2-hydroxyethyl)dithiocarbamate, K[bhedtc] (1) and potassium O-[2-[bis(2-hydroxyethyl)amino]ethyl]dithiocarbonate hemihydrate, K[bhexan]·0.5H2O (2). In this work, cell viability was measured as a function of chelator concentration (0-1000 μM) and administration delay post cadmium inoculation (0-16 hrs). Upon simultaneous administration, cytotoxicity mediated by the presence of 100 μM CdCl2 was best alleviated by the presence of 100 μM chelator 1. Chelator 2 was much less potent: optimal alleviation was attained at 1000 μM (1 mM) 2. Relief from cadmium toxicity was still afforded by 100-500 μM chelator 1 or 600-1000 μM chelator 2 administered up to 8 hours after 100 μM CdCl2. However, cell viability lower than that exhibited by 100 μM CdCl2 (the -control) was observed for chelator 1 when the delay was extended to 16 hours. These results indicate that chelator 1 is more potent at alleviating cadmium-mediated cytotoxicity, but its effectiveness is more sensitive to administration delay than that of chelator 2. Overall this work has demonstrated a method to evaluate the efficacy of chelators to alleviate cadmium-mediated cytotoxicity.

Megan K. Judkins, Paris S. Humphries, and Peter R. Craig "Evaluation of chelators administered to rescue human bone cells from cadmium toxicity," BIOS 85(1), 57-66, (1 March 2014).
Received: 6 November 2012; Accepted: 1 August 2013; Published: 1 March 2014

Get copyright permission
Back to Top